ceftobiprole and Soft-Tissue-Infections

Ceftaroline and ceftobiprole are advanced generation cephalosporins with activity against methicillin-resistant Staphylococcus aureus (MRSA). This review summarizes their clinical efficacy for complicated skin and soft tissue infections (cSSTIs).. Both these agents retain excellent in vitro activity against both MRSA and Gram-negative isolates from patients with CSSTIs. Both these agents are registered for the management of cSSTIs based on the results of large scale phase III noninferiority trials. Ceftaroline and ceftobiprole are noninferior to the combination of vancomycin and aztreonam as this was assessed by their clinical cure rate at the test-of-cure visits. Furthermore, ceftobiprole is noninferior to comparators for the achievement of early clinical success at 72 h. Ceftaroline achieves 81% clinical cure against diabetic foot infections.. Ceftaroline and ceftobiprole can be used as monotherapy for the treatment of cSSTIs.

Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Soft Tissue Infections; Staphylococcal Infections

Ceftobiprole is a fifth-generation cephalosporin approved for the treatment of adult community-acquired pneumonia and non-ventilator associated hospital-acquired pneumonia. However, its microbiological and pharmacokinetic profile is very attractive as armamentarium for empirical monotherapy treatment in other infections too. Among these, the following scenarios could be considered complicated skin and soft tissue infections, moderate-severe diabetic foot infections without bone involvement, vascular-catheter-associated-bloodstream infections, and fever without apparent focus in the hospitalized patient without septic shock or profound immunosuppression.

Topics: Anti-Bacterial Agents; Bacterial Infections; Catheter-Related Infections; Cephalosporins; Cross Infection; Diabetic Foot; Fever of Unknown Origin; Humans; Inpatients; Pneumonia, Bacterial; Skin Diseases, Bacterial; Soft Tissue Infections

Topics: Cephalosporins; Humans; Methicillin Resistance; Soft Tissue Infections; Staphylococcal Infections; Staphylococcal Skin Infections; Staphylococcus aureus